hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy

por Muratori, Leonardo, Petroni, Giulia, Antonuzzo, Lorenzo, Boni, Luca, Iorio, Jessica, Lastraioli, Elena, Bartoli, Gianluca, Messerini, Luca, Di Costanzo, Francesco, Arcangeli, Annarosa
Publicado 2016

The combined activation of K(Ca)3.1 and inhibition of K(v)11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells

por Pillozzi, Serena, D'Amico, Massimo, Bartoli, Gianluca, Gasparoli, Luca, Petroni, Giulia, Crociani, Olivia, Marzo, Tiziano, Guerriero, Angela, Messori, Luigi, Severi, Mirko, Udisti, Roberto, Wulff, Heike, Chandy, K George, Becchetti, Andrea, Arcangeli, Annarosa
Publicado 2018